Nordea Investment Management Reduces Omnicell Stake

Institutional investor sells 17,304 shares of healthcare technology company

Mar. 27, 2026 at 9:36am

Got story updates? Submit your updates here. ›

Nordea Investment Management AB decreased its position in Omnicell, Inc. (NASDAQ:OMCL) by 13.6% in the 4th quarter, according to a recent SEC filing. The institutional investor now owns 110,267 shares of the company's stock, down from 127,571 shares previously.

Why it matters

This transaction reflects Nordea's reduced confidence in Omnicell's near-term prospects, potentially signaling broader market uncertainty around the healthcare technology company's performance. Omnicell provides medication management solutions to hospitals, clinics and pharmacies, an industry facing headwinds from cost pressures and regulatory changes.

The details

Nordea Investment Management sold 17,304 shares of Omnicell, reducing its total stake to 110,267 shares worth $5,027,000 as of the end of the 4th quarter. Several other hedge funds have also recently modified their holdings of Omnicell, with some increasing and others decreasing their positions.

  • Nordea Investment Management reduced its Omnicell stake in the 4th quarter of 2025.

The players

Nordea Investment Management AB

A major institutional investor that manages over $400 billion in assets globally.

Omnicell, Inc.

A healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies.

Got photos? Submit your photos here. ›

The takeaway

Nordea's reduced stake in Omnicell reflects broader uncertainty around the healthcare technology sector, which is facing headwinds from cost pressures and regulatory changes. This transaction highlights the volatility that can impact even large, established players in the space.